WebIn the primary efficacy population (N=46), the IRC-assessed objective response rate at EOI was 76%, with a CR rate of 61%. The best overall response rate by investigator assessment (INV) was 91%, with a best CR rate of 72%. After a median follow-up of 43.3 months in the efficacy-evaluable population (N=46), median PFS was not reached ( … WebNov 14, 2024 · In the efficacy evaluable population of patients who had platinum resistant, measurable disease, and received at least one dose (104 patients), the confirmed ORR …

Facebook - NCI

WebMar 15, 2024 · Within the efficacy evaluable population, the overall response rate was 53% (32/60) with a CR/CRh rate of 30% (18/60), and 78% (14/18) of patients with CR/CRh attaining measurable residual disease (MRD) negativity. The median time to CR/CRh response in the trial was 1.9 months, and the median duration of CR/CRh response was … WebOct 26, 2024 · Vaccine Efficacy in Participants . Without. Evidence of Infection Prior to 7 Days After Dose 2 (5-11 Years of Age Evaluable Efficacy Population) BNT162b2 10 crif zarobki

Effective Population Size Concept, Equation & Examples - Video ...

WebApr 14, 2024 · Median DoR was 14.4 months, 8.9 months, not reached, 7.7 months, not reached, 31.2 months, not reached and 11.1 months, respectively. Median PFS was 6.7 … WebApr 14, 2024 · Efficacy evaluable population: Primary and expansion cohorts in all except low grade glioma and multiple myeloma which are primary analysis cohorts. ATC: Among 36 patients, 24 (67%) patients died ... WebMar 31, 2024 · However, efficacy and safety studies on this population are limited. Nebhan et al. 18 reported that median PFS was 6.7 months and OS was 10.9 months in 345 patients aged ≥80 years. In our study, we enrolled 38 patients ≥80 years of age, and PFS and OS in these patients were comparable to those of the patients aged <80 years old. اسم با م پسرانه